<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570319</url>
  </required_header>
  <id_info>
    <org_study_id>ACNE.PROBI</org_study_id>
    <nct_id>NCT04570319</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Effect of a Probiotic in Acne</brief_title>
  <official_title>A Randomized, Double Blind and Placebo-Controlled Clinical Trial to Evaluate the Effect of a Probiotic in Patients With Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionou Research, S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionou Research, S.L.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week randomized, multicenter and double-blind, placebo-controlled pilot study to&#xD;
      evaluate the effect of a probiotic in the clinical and subjective evolution of acne in&#xD;
      adolescent and adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne is a chronic inflammatory disease of the skin that affects 85% of younger adults in&#xD;
      westernized populations. Acne pathophysiology is multifactorial and may include alterations&#xD;
      of the pilosebaceous unit function, skin microbiota, hormone imbalance and gut microbiota.&#xD;
      Acne pathology shares features with inflammatory chronic conditions such as metabolic&#xD;
      syndrome, obesity or diabetes.&#xD;
&#xD;
      Probiotics are live microorganisms that when administered in adequate amounts confer a health&#xD;
      benefit for the host. Probiotics are proposed for the treatment of inflammatory chronic&#xD;
      conditions, including dermatological diseases as atopic dermatitis and psoriasis. However,&#xD;
      the clinical evidence is limited. Therefore, usefulness of probiotics for acne vulgaris&#xD;
      treatment must be ascertained in humans.&#xD;
&#xD;
      This randomized study aims to evaluate the effect of a probiotic on the treatment and&#xD;
      clinical and subjective evolution of acne vulgaris.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the AGSS (Acne Global Severity Scale) index at 12 weeks</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>Score between 0 and 5:&#xD;
0: Clean = Normal and clear skin without evidence of acne&#xD;
Almost clean = There are some non-inflammatory lesions, with uncommon and non-inflamed papules&#xD;
Mild = few inflammatory lesions (no nodule-cystic lesions)&#xD;
Moderate = Noninflammatory lesions predominate, but multiple inflammatory lesions appear (nodule-cystic lesions may be present)&#xD;
Severe = Inflammatory lesions predominate (nodule-cystic lesions may be present)&#xD;
Very severe = Highly inflammatory lesions predominate (several nodule-cystic lesions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the GAGS (Global Acne Grading System) index at week 12</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>TOTAL SCORE = [Nose S x 1 + Chin S x 1 + Front S x 2 + Right cheek S x 2 + Left cheek S x 2 + Torso S x 3]&#xD;
[Severity (S): 0 = Absence; 1 = Comedones; 2 = Papules; 3 = Pustules; 4 = Nodules]&#xD;
SCORE: 0 = Clean; 1-18 = Mild; 19-30 = Moderate; 31-38 = Severe; &gt; 38 = Very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the number of acne lesions at week 12</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>Number of non-inflammatory, inflammatory and total acne lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in the patient subjective evaluation index at week 12</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>Min score (Best) = 6 Max score (Worst) = 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antibiotic acne treatment</measure>
    <time_frame>12-week</time_frame>
    <description>Days of antibiotic use for the acne treatment, registered by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of patients with presence of Cutibacterium acnes and Staphylococcus aureus in skin microbiome</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>Skin sample and genomic and microbiological analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the microbiome components on stool samples</measure>
    <time_frame>0 and 12-week</time_frame>
    <description>Stool sample and high-throughput sequencing data analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>12-week</time_frame>
    <description>Compliance rate (in percentage) calculated as the number of leftover capsules divided by the total number of days between visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety assessed by number of adverse events</measure>
    <time_frame>12-week</time_frame>
    <description>Number of adverse events that occur during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acne</condition>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Probiotic Bths-08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a capsule containing the probiotic blend (nutritional complement)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a capsule containing placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Bths-08</intervention_name>
    <description>A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks</description>
    <arm_group_label>Probiotic Bths-08</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signature of informed consent by the patient (and their legal guardian in case of&#xD;
             being under age).&#xD;
&#xD;
          -  Age between 12 and 30 years-old.&#xD;
&#xD;
          -  AGSS (Acne Global Severity Scale) Score: 2 or higher&#xD;
&#xD;
          -  Patients who agree to follow the study's dietary recommendations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication of any of the components of the product under study.&#xD;
&#xD;
          -  Topical or systemic use of antifungals and antibiotics in the previous 2 weeks.&#xD;
&#xD;
          -  Consumption of probiotics in the previous 2 months.&#xD;
&#xD;
          -  Use of systemic retinoids in the previous 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Navarro-Lopez, PhD; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Católica San Antonio de Murcia (UCAM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Navarro-Moratalla</last_name>
    <phone>623022586</phone>
    <email>administracion@bionou.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidad Católica San Antonio de Murcia</name>
      <address>
        <city>Guadalupe</city>
        <state>Murcia</state>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Navarro</last_name>
      <email>vnavarro@ucam.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Dermatológico Estético de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Vela</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Eguren Dermatología y Estética</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Eguren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Nisa 9 de Octubre-Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Acne</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Symbiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

